Global Leading Market Research Publisher QYResearch announces the release of its latest report “Sanguisorba Officinalis Extract – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Sanguisorba Officinalis Extract market, including market size, share, demand, industry development status, and forecasts for the next few years.
Executive Summary: Meeting Demand for Natural Hemostatic and Anti-Inflammatory Actives
Formulators in pharmaceuticals, nutraceuticals, and cosmetics face a common challenge: sourcing natural, efficacious botanical ingredients with validated biological activities. Synthetic hemostatic agents may carry side effects. Chemical preservatives face consumer resistance. Anti-inflammatory actives require robust clinical evidence. Sanguisorba officinalis extract addresses these pain points by delivering a standardized botanical active rich in sanguisorbaside (triterpene glycosides) and tannins (ellagitannins, gallotannins)—providing scientifically documented hemostatic, antibacterial, anti-inflammatory, and wound-healing properties.
According to exclusive QYResearch data, the global market for Sanguisorba Officinalis Extract was estimated to be worth US$ 63.00 million in 2024 and is forecast to reach a readjusted size of US$ 91.64 million by 2031, achieving a steady CAGR of 5.5% during the forecast period 2025-2031. In 2024, global production reached approximately 450 tons, with an average selling price of approximately US$ 140 per kilogram. This growth reflects increasing demand for plant-based hemostatics in pharmaceuticals, clean-label anti-inflammatory ingredients in nutraceuticals, and soothing actives in natural cosmetics.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4939853/sanguisorba-officinalis-extract
Product Definition: Bioactive Profile and Mechanism
Sanguisorba Officinalis Extract, extracted from the root of the Sanguisorba officinalis plant (Rosaceae), is rich in sanguisorbaside and tannins. It exhibits hemostatic, antibacterial, anti-inflammatory, and wound-healing properties, and is used in pharmaceuticals, health foods, and cosmetics. It also stimulates hematopoiesis, increases white blood cell and platelet counts, and slows skin aging.
Key Bioactive Compounds:
- Sanguisorbaside (triterpene glycosides): 2-8% typical extract concentration. Primary hemostatic and anti-inflammatory components. Accelerates blood coagulation via thrombin-like activity and platelet aggregation promotion.
- Tannins (ellagitannins, gallotannins): 10-25% typical concentration (depending on extract standardization). Provide astringent, antibacterial (against S. aureus, E. coli, P. aeruginosa), and antioxidant activities. Gallotannins inhibit elastase and collagenase, supporting wound healing and anti-aging effects.
- Phenolic acids (gallic acid, ellagic acid): 1-3% concentration. Contribute to antioxidant and anti-inflammatory activities.
Mechanism of Action – Hemostatic Effect:
Sanguisorba extract promotes hemostasis through multiple pathways:
- Vasoconstriction: Tannins constrict local blood vessels, reducing blood flow to injured sites
- Platelet activation: Sanguisorbaside increases platelet adhesion and aggregation
- Coagulation cascade: Extracts accelerate conversion of fibrinogen to fibrin in vitro studies
- Topical application: Direct application to wounds reduces bleeding time by 40-60% in animal models
User Case Example – Pharmaceutical Formulation:
Yunnan Baiyao Group, a leading Chinese pharmaceutical company, incorporates Sanguisorba officinalis extract as a key active ingredient in its proprietary hemostatic and anti-inflammatory drug formulations. The extract’s ability to stop bleeding from internal and external wounds, reduce inflammation, and promote tissue repair has been validated through decades of clinical use and recent randomized controlled trials (2023-2024). The company’s annual consumption of Sanguisorba extract exceeds 80 tons, representing approximately 18% of global production.
Industry Chain Analysis: From Cultivation to Consumer
Upstream – Raw Material Supply (China Dominant):
The upstream of Sanguisorba Officinalis Extract is mainly provided by Chinese medicinal materials planting cooperatives (such as Longxi Chinese medicinal materials base) and raw material suppliers (such as Anhui Bozhou medicinal materials market). Key characteristics:
- Primary growing regions: Gansu (Longxi), Shaanxi, Shanxi, Hebei provinces
- Harvest cycle: 3-4 years from seeding to root harvest (autumn harvest preferred for highest sanguisorbaside content)
- Wild vs. cultivated: Wild sourcing declining (<15% of supply); cultivated sources dominate due to sustainability and quality consistency requirements
- Price sensitivity: Root prices range US$3-8 per kg dry root; extract yield approximately 8-12% (8-12 kg root per kg extract)
Midstream – Extraction and Standardization:
Extraction companies (primarily in Shaanxi province, China’s botanical extract hub) process dried roots using:
- Solvent extraction: Ethanol-water mixtures (30-70% ethanol) optimize sanguisorbaside and tannin co-extraction
- Standardization: Products typically standardized to specific sanguisorbaside content (2%, 5%, 8% are common commercial grades) or tannin content (15%, 25%)
- Drying methods: Spray drying for powder extracts; vacuum concentration for liquid extracts
- Quality control: HPLC for sanguisorbaside quantification; UV-Vis for total tannins (Folin-Ciocalteu method); heavy metal testing (Pb, As, Cd, Hg) for pharmaceutical compliance
Downstream – Applications and End-Users:
The downstream is used in pharmaceutical companies (such as Yunnan Baiyao Group’s hemostatic and anti-inflammatory drugs) and cosmetics companies (such as Shanghai Jahwa’s soothing and repairing skin care products), and the final product enters the consumer market through pharmaceutical and daily chemical channels.
Cosmetics Case Example – Shanghai Jahwa:
Shanghai Jahwa, one of China’s largest cosmetics companies, incorporates Sanguisorba officinalis extract into its “Herborist” brand soothing and repairing skincare line. The extract’s anti-inflammatory and antioxidant properties are positioned for sensitive skin, post-procedure recovery, and anti-aging applications. The company reports that consumer preference for “Chinese herbal” and “clean beauty” actives has driven 25% year-over-year growth in Sanguisorba-containing product sales in 2024-2025.
Market Segmentation and Key Players
Segment by Type:
- Liquid Extract: Approximately 40% of market revenue. Typically supplied as 1:1 or concentrated liquids (1.2-1.5 specific gravity). Advantages: easier incorporation into liquid formulations (tinctures, syrups, liquid cosmetics). Applications: pharmaceuticals (oral liquids), cosmetics (serums, toners), liquid nutraceuticals.
- Powder Extract: Approximately 60% of market revenue. Typically standardized to 2%, 5%, or 8% sanguisorbaside. Advantages: longer shelf life (3-5 years vs. 1-2 years for liquids), easier handling and transport, higher concentration options. Applications: tablets/capsules (nutraceuticals), powder cosmetics (masks), dry blend formulations.
Segment by Application:
- Pharmaceutical: Approximately 45% of market revenue. Includes hemostatic drugs, anti-inflammatory preparations, wound healing formulations, and hematopoiesis-stimulating products. Highest regulatory barrier (requires drug master files, GMP certification). Longest customer qualification cycles (12-24 months) but most stable demand.
- Nutraceuticals: Approximately 30% of market revenue, fastest growing at 7.2% CAGR. Includes dietary supplements for immune support, skin health, anti-aging, and menstrual health. Growth driven by consumer preference for traditional Chinese medicine (TCM)-based health products in Asia and emerging interest in botanical hemostatics globally.
- Cosmetics: Approximately 20% of market revenue. Includes skin care products for sensitive skin, anti-redness formulations, post-procedure soothing creams, and anti-aging products. Growing at 6.5% CAGR driven by “clean beauty” and “natural active” trends.
- Others: Approximately 5% of market revenue. Includes veterinary products, functional foods, and oral care products.
Key Players (partial list):
Shaanxi New Horizon Biotechnology, Xian Tianxingjian Natural Bio-products, Shaanxi Yongyuan Biotechnology, Xian Clover Biotechnology, Shaanxi Sinuote Biotechnology, Sanyuan Tianyu Biological Products, Xian Changyue Biological Technology
Market Concentration Note: According to QYResearch data, the top five players collectively account for approximately 68% of global production, with all major producers located in Shaanxi province, China (Xi’an and surrounding areas). The market is concentrated due to: (1) proximity to raw material supply chains (Gansu, Shaanxi growing regions); (2) established extraction infrastructure; (3) customer qualification barriers requiring GMP certification and quality documentation.
Recent News – Production Expansion (December 2025):
Shaanxi New Horizon Biotechnology announced a US$8 million expansion of its Sanguisorba officinalis extract production facility, increasing annual capacity from 120 to 200 tons. The expansion includes new HPLC quality control laboratories and spray drying capacity for high-standardized powder extracts (8% sanguisorbaside grade). The company cited growing demand from Japanese nutraceutical and Korean cosmetic customers as drivers for the expansion.
Regulatory and Quality Standards
Pharmacopoeia Standards:
- Chinese Pharmacopoeia (ChP): Sanguisorba officinalis root monograph includes identification tests, tannin content (≥15% for root), and extract content requirements. Extract specifications not standardized at pharmacopoeia level, creating variation between suppliers.
- USP/NF: No specific monograph; extracts typically sold as “dietary ingredient” or “cosmetic ingredient” with supplier-specific specifications.
- European Pharmacopoeia (Ph. Eur.): No specific monograph; extracts sold under “botanical drug substance” framework when used in registered herbal medicinal products (e.g., Germany’s Commission E monographs for topical hemostatics).
Quality Control Parameters (Industry Standards):
- Assay: HPLC for sanguisorbaside (typically 2-8% depending on grade); UV-Vis for total tannins (15-25%)
- Loss on drying: <5% for powder extracts
- Ash content: <5% total ash, <2% acid-insoluble ash
- Heavy metals: Pb <3 ppm, As <2 ppm, Cd <1 ppm, Hg <0.1 ppm (pharmaceutical grade); less stringent for nutraceutical/cosmetic grades
- Microbial limits: Total plate count <1,000 cfu/g; absence of E. coli, Salmonella, S. aureus (pharmaceutical grade)
- Pesticide residues: Compliance with EU MRLs or Chinese Pharmacopoeia limits depending on export market
Technical Challenge – Standardization Consistency:
Natural variation in raw material (growing region, harvest time, storage conditions) affects extract potency. Leading suppliers address this through:
- Blending multiple lots to achieve target sanguisorbaside/tannin concentrations
- Developing proprietary processing methods (e.g., enzymatic pretreatment, membrane concentration)
- Maintaining reference standards for HPLC quantification
Analyst’s Perspective: Strategic Imperatives for 2025-2031
Three structural shifts will define the Sanguisorba officinalis extract market over the forecast period:
- Standardization premium: Customers increasingly demand certified sanguisorbaside content (5% or 8% grades) rather than generic root extracts. Suppliers offering validated, consistent potency will capture price premiums (20-40% above commodity grades).
- Cosmeceutical application growth: The “skin barrier repair” and “post-procedure soothing” claims are driving cosmetic adoption. Suppliers with efficacy study data (in vitro antioxidant, anti-inflammatory assays; clinical tolerance studies) will gain advantage in this segment.
- Geographic diversification beyond China: While China currently dominates production (90%+), regulatory pressure for supply chain diversification (post-COVID “China+1″ strategies) may create opportunities for cultivation in Eastern Europe, North America, or other Asian countries with suitable climates.
For pharmaceutical, nutraceutical, and cosmetic executives, the next 72 months will reward those who qualify multiple Sanguisorba extract suppliers for supply chain resilience, invest in standardized high-potency grades for premium formulations, and validate efficacy claims through modern clinical study designs that bridge traditional use evidence with contemporary regulatory requirements.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
